In each of the lines that demonstrated a maintained complete response to glembatumumab vedotin (OS-2, OS-17, and OS-33), there is 2+ to 3+ staining for GPNMB by immunohistochemistry, although the percentage of cells positive is as low as 5% of tumor cells for one line. Here, GPNMB is linked to neoplasm.